Test Bank - Pharmacology: A Patient-Centered Nursing Process Approach (9th Edition) PHARMACOLOGY 9TH EDITION MCCUISTION TEST BANK

PHARMACOLOGY 9T`
wo

, TestwoBankwo-woPharmacology:woAwoPatient-
CenteredwoNursingwoProcesswoApproachwo(9thwoEdition,wo2017)
PHARMACOLOGYwo9THwoEDITIONwoMCCUISTIONwoTESTwoBANK


TablewoofwoContents
TablewoofwoContents Chapterwo28:woPeptid
es,woAntimalarial,woan
d
Chapterwo01:woDrugwoDevelopmentw Chapterwo27:woAntituberculars,woAntifung
oandwoEthicalwoConsiderations als,woandwoAntivirals
Chapterwo02:woPharmacokineti
cs,woPharmacodynamics,woand
woPharmacogenetics
Chapterwo03:woCulturalwoConsiderati
onswoChapterwo04:woComplementar
ywoandwoAlternativewoTherapies
Chapterwo05:woPediatricwoConsiderati
onswoChapterwo06:woGeriatricwoConsi
derationswoChapterwo07:woDrugswoinw
oSubstancewoUsewoDisorder
Chapterwo08:woThewoNursingwoProces
swoandwoPatient-CenteredwoCare
Chapterwo09:woSafetywoandwoQu
alitywoChapterwo10:woDrugwoAdm
inistrationwoChapterwo11:woDrugw
oCalculationswoChapterwo12:woFl
uidwoVolumewoandwoElectrolytes
Chapterwo13:woVitaminwoandwoMi
neralwoReplacement
Chapterwo14:woNutritionalwoSupportwo
Chapterwo15:woAdrenergicwoAgonists
woandwoAntagonists
Chapterwo16:woCholinergicwoAgonistsw
oandwoAntagonists
Chapterwo17:woStimulants
Chapterwo18:woDepressantswo
Chapterwo19:woAntiseizurewoDr
ugs
Chapterwo20:woDrugswoforwoParkinsonis
mwoandwoAlzheimer'swoDisease
Chapterwo21:woDrugswoforwoNeuromus
cularwoDisorderswoandwoMusclewoSpa
smswoChapterwo22:woAntipsychoticswo
andwoAnxiolytics
Chapterwo23:woAntidepressantswoandwo
MoodwoStabilizers
Chapterwo24:woAntiinflammatories
Chapterwo25:woAnalgesics
Chapterwo26:woAntibacterials

, TestwoBankwo-woPharmacology:woAwoPatient-
CenteredwoNursingwoProcesswoApproachwo(9thwoEdition,wo2017)
PHARMACOLOGYwo9THwoEDITIONwoMCCUISTIONwoTESTwoBANK
Anthelmintic
Chapterwo29:woHIV-woandwoAIDS-
RelatedwoDrugs
Chapterwo30:woTransplantwoD
rugswoChapterwo31:woVaccin
eswoChapterwo32:woAnticance
rwoDrugs
Chapterwo33:woTargetedwoTherapieswoto
woTreatwoCancer
Chapterwo34:woBiologicwoResp
onsewoModifiers
Chapterwo35:woUpperwoRespir
atorywoDisorders
Chapterwo36:woLowerwoRespir
atorywoDisorders
Chapterwo37:woCardiacwoGlycoside
s,woAntianginals,woandwoAntidysrhy
thmicswoChapterwo38:woDiuretics
Chapterwo39:woAntihypertensive
Chapterwo40:woAnticoagulants,woAnt
iplatelets,woandwoThrombolyticswoC
hapterwo41:woAntihyperlipidemicswo
andwoPeripheralwoVasodilators
Chapterwo42:woGastrointestinalwo
TractwoDisorders
Chapterwo43:woAntiulcerwoDrugswoC
hapterwo44:woEyewoandwoEarwoDisor
derswoChapterwo45:woDermatologic
woDisorderswoChapterwo46:woPituitar
y,woThyroid,woParathyroid,woandwoA
drenalwoDisorderswoChapterwo47:wo
Antidiabetics
Chapterwo48:woUrinarywoDisorderswo
Chapterwo49:woPregnancywoandwoPr
etermwoLabor
Chapterwo50:woLabor,woDelivery,
woandwoPostpartum
Chapterwo51:woNeonatalwoandwoNe
wbornwoChapterwo52:woWomen'swo
ReproductivewoHealth
Chapterwo53:woMen'swoReproductivewo
HealthwoChapterwo54:woSexuallywoTran
smittedwoInfections
Chapterwo55:woAdultwoandwoPe
diatricwoEmergencywoDrugs

, TestwoBankwo-woPharmacology:woAwoPatient-
CenteredwoNursingwoProcesswoApproachwo(9thwoEdition,wo2017)
PHARMACOLOGYwo9THwoEDITIONwoMCCUISTIONwoTESTwoBANK




Chapterwo01:woDrugwoDevelopmentwoandwoEthicalwoConsideration
s
MULTIPLEwoCHOICE
1. ThewonursewoiswopreparingwotowoadministerwoawoschedulewoIIwoinjectablewodrugwoandwois
wodrawingwoupwohalfwoofwothewocontentswoofwoawoSingle-
usewovial.woWhichwonursingwoactionwoiswocorrect?
a. Askwoanotherwonursewotowoobservewoandwocosignwowastingwotheworemainingwodrugwofromwoth
ewovial.
b. Keepwotheworemainingwoamountwoinwothewopatient’swodrawerwotowogivewoatwothewonextwodose.
c. Recordwothewoamountwounusedwoinwothewopatient’swomedicationworecord.
d. Disposewoofwothewovialwowithwotheworemainingwodrugwointowoawolocked
wocollectionwobox.woANS:woA
SchedulewoIIwodrugswoarewocontrolledwosubstances,woandwoallwomustwobewoaccountedwofor.
woWhenwowastingwoawoportionwoofwoawodrug,woanotherwonursewoshouldwoobservewoandwoco
signwothatwoawodrugwowaswowasted.
DIF:woCOGNITIVEwoLEVEL:woApplyingwo(Applic
ation)woTOP:woNURSINGwoPROCESS:woNursing
woIntervention
MSC:woNCLEX:woPhysiologicalwoIntegrity:woPharmacologicalwoandwoParenteralwoTherapies

2. Awopatientwoiswoprescribedwoawomedicationwoandwoaskswothewonursewoifwothewodrugwoiswo
availablewoinwoawogenericwoform.woThewonursewounderstandswothatwoawogenericwomedicatio
nwowillwohavewoawonamewothat
a. iswoaworegisteredwotrademark.
b. iswoalwayswocapitalized.
c. describeswothewodrugswochemicalwostructure.
d. iswonon-
proprietary.woANS:w
oD
Thewogenericwonamewoiswothewoofficial,wonon-
proprietarywonamewoforwoawodrug.woThewobrandwonamewoiswothewotrademarkwonamewoandwoisw
oalwayswocapitalized.woThewochemicalwonamewodescribeswothewochemicalwostructurewoofwothew
odrug.
DIF:woCOGNITIVEwoLEVEL:woUnderstandingwo(Comprehe
nsion)woTOP:woNURSINGwoPROCESS:woN/A
MSC:woNCLEX:woPhysiologicalwoIntegrity:woPharmacologicalwoandwoParenteralwoTherapies

3. Awopatientworeceiveswoawoprescriptionwoonwowhichwothewoproviderwohaswonotedwothatwoaw
ogenericwomedicationwomaywobewogiven.Thewopatientwoaskswothewonursewowhatwothiswomea
ns.woWhatwowillwothewonursewotellwothewopatientwoaboutwogenericwodrugs?
a. Theywocontainwothewosamewoinertwoingredientswoaswobrand-namewodrugs.
b. Theywohavewochemicalwostructureswothatwoarewoidenticalwotowoproprietarywodrugs.
c. Theywotendwotowobewolesswoexpensivewothanwobrand-namewodrugs.
d. Theywoundergowoextensivewotestingwobeforewotheywoarew
omarketed.woANS:woC
GenericwodrugswoarewoapprovedwobywothewoFDAwoifwotheywoarewoprovedwotowobewobioequivale
ntwotowothewobrand-